Epcoritamab plus rituximab and lenalidomide improves efficacy in relapsed or refractory follicular lymphoma
Supporting oncology professionals through education
The content on this site is intended for healthcare professionals only
The content on this site is intended for healthcare professionals only
Epcoritamab plus rituximab and lenalidomide improves efficacy in relapsed or refractory follicular lymphoma
The Vanessa Moss Prize: celebrating research into cancer health disparities
Climate and environmental factors drive seasonal risk of invasive mucormycosis in haematologic malignancies
Extreme heat exposure around diagnosis is linked to higher mortality in multiple myeloma
Can public–private partnerships accelerate cancer research and clinical trials in LMICs?
Oral cancer prevention through community counselling in a tribal population
Global cancer burden, prevention, and inequalities across regions
Understanding breast cancer care systems with the BCCi
Strengthening cancer prevention through the Latin American cancer code
Reducing cancer burden through prevention
The tobacco industry's influence on science and healthcare professionals
How the tobacco industry shapes science to protect profits